IL6 and hepatocellular carcinoma: Clinical evidence from a meta-analysis of 18 studies involving patients with HCC and hepatitis revealed a progressive elevation in serum IL-6 levels with disease progression, from healthy individuals to hepatitis, cirrhosis, and ultimately HCC (7).